Quest Diagnostics Awarded Contract To Assess Burden Of Hepatitis C Virus In U.S By CDC
(RTTNews) - Quest Diagnostics (DGX), a leading provider of hepatitis testing services, announced Thursday it has been awarded a contract by the U.S. Centers for Disease Control and Prevention (CDC) designed to assess the burden of hepatitis C virus (HCV) in the U.S.
Quest was awarded a multi-year agreement following a competitive bid. The agreement marks a new phase of a decade-long collaboration between Quest and the CDC to improve hepatitis public health research based on insights from laboratory data.
Under the new agreement, Quest will perform both HCV antibody testing and molecular RNA testing using HIPAA-deidentified "remnant" specimens randomly selected from clinical test specimens. The goal is to gain a better understanding of the burden of hepatitis C infection in the United States.
Quest will provide research consulting, laboratory testing and data analytics services to generate diagnostics insights supporting population health strategy for hepatitis C.
Haystack Oncology And Lisata Therapeutics Partner To Evaluate Efficacy Of Pancreatic Cancer Therapy
Quest Diagnostics To Acquire Outreach Laboratory Services Of OhioHealth
Quest Diagnostics To Acquire LifeLabs From OMERS In About $985 Mln Deal
Quest, Scipher Team Up To Expand Diagnostic Services Access For Patients With Rheumatoid Arthritis
Quest Diagnostics Narrows FY23 Adj. EPS Outlook Range, Boosts Revenue Forecast - Update
Quest Diagnostics Says FDA Grants Breakthrough Designation For Adeno-associated Virus Test
Quest Diagnostics Boosts FY23 Adj. EPS, Revenue Outlook - Update
